BioAge Labs, Inc. (BIOA)

In January 2026, BioAge completed an upsized follow-on public offering, raising approximately $132.3 million. In April 2026, BioAge reported positive topline data from the Phase 1 trial of BGE-102, showing significant hsCRP reductions. On May 8, 2026, BioAge reported its first-quarter 2026 financial results, highlighting increased collaboration revenue and larger operating loss due to increased development investments. As of April 28, 2026, the share price was $17.45, representing a significant increase from $4.33 on April 29, 2025, and as of May 9, 2026, the stock price was $17.99.

Specific information on demand seasonality for BioAge Labs, Inc.'s products and services is not readily available, as its revenue model is primarily based on potential licensing agreements, milestone payments, and future product sales. Stock price seasonality analysis suggests that February has historically offered the highest probability of positive returns for BIOA, while May has a 50% probability of positive returns.

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic diseases by targeting the biology of human aging, leveraging its technology platform and human datasets to identify molecular changes that drive aging. Its pipeline includes BGE-102, an NLRP3 inhibitor for cardiovascular risk and retinal diseases, APJ Agonists for obesity and related metabolic indications, and previously Azelaprag, which was terminated due to safety concerns. BioAge collaborates with Novartis Pharma AG to identify and validate novel therapeutic drug targets.

BioAge Labs, Inc. is headquartered in Emeryville, California, United States, with its corporate office located in Richmond, CA. The company's operations are managed as one segment focused on extending healthy human life by targeting molecular causes of aging.

BioAge Labs' reputation has been impacted by the discontinuation of the STRIDES Phase 2 trial for azelaprag due to safety concerns, leading to a stock value drop and shareholder lawsuits alleging misrepresentation of the drug's safety profile. Despite these challenges, the company has reported positive developments for its other pipeline candidates, such as BGE-102.

BioAge Labs, Inc. has significant institutional ownership, with 117 institutional owners and shareholders holding a total of 23,769,828 shares as of May 4, 2026, representing 54.35% ownership, while insider ownership is 2.59%. Major institutional and individual owners include AH Capital Management, L.L.C., Sofinnova Investments, Inc., Cormorant Asset Management, LP, BlackRock, Inc., Vanguard Group Inc, Vijay Satyanand Pande, James Healy, Patrick G. Enright, and Kristen Fortney.